Drug Profile
Estradiol/testosterone transdermal - Procter & Gamble/Watson
Alternative Names: Testosterone/estradiol transdermal - WatsonLatest Information Update: 11 Apr 2008
Price :
$50
*
At a glance
- Originator Watson Laboratories
- Class Estradiol congeners; Estrenes; Hormonal replacements; Testosterone congeners
- Mechanism of Action Estrogen receptor agonists; Testosterone agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Female sexual dysfunction; Menopausal syndrome; Postmenopausal osteoporosis
Most Recent Events
- 27 Jun 2006 No development reported - Phase-I for Female sexual dysfunction in USA (Transdermal)
- 27 Jun 2006 No development reported - Phase-I for Menopausal syndrome in USA (Transdermal)
- 27 Jun 2006 No development reported - Phase-I for Postmenopausal osteoporosis in USA (Transdermal)